Reduced-intensity versus myeloablative allogeneic transplantation

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Allotransplantation cures patients by cytoreduction and the graft-versus-tumor (leukemia; graft-versus-leukemia [GVL]) alloresponse; both eliminate residual disease. The spectrum of conditioning intensity influences toxicities and non-relapse mortality. The spectrum of tumor sensitivity to the GVL response influences relapse. Balancing tolerable toxicities (influenced by patients’ performance status and comorbidities) is also influenced by the graft. Intense immunosuppression (for engraftment and graft-versus-host disease prevention) may constrain the immunologic potency of the graft and limit the antineoplastic capacity of the transplant, thus requiring more intense or more effective conditioning regimens to limit the risks of relapse and permit satisfactory disease-free survival.

Original languageEnglish (US)
Pages (from-to)321-326
Number of pages6
JournalHematology/ Oncology and Stem Cell Therapy
Issue number4
StatePublished - Dec 2017

Bibliographical note

Publisher Copyright:
© 2017 King Faisal Specialist Hospital & Research Centre


  • Conditioning intensity
  • Graft versus leukemia
  • Myeloablative
  • Reduced intensity
  • Stem cell transplantation


Dive into the research topics of 'Reduced-intensity versus myeloablative allogeneic transplantation'. Together they form a unique fingerprint.

Cite this